Harrow Health (HROW) insider buying
10 open-market purchases of HROW by Harrow Health's executives and directors since August 2023, worth $3M in total, from SEC Form 4 filings.
The most recent: Opaleye Management Inc. bought $199,400 on April 25, 2024.
The biggest buyer over the period is Opaleye Management Inc.: 6 purchases, $2M.
By year
| Year | Purchases | Value |
|---|---|---|
| 2024 | 6 | $2M |
| 2023 | 4 | $703,464 |
Biggest buyers
| Insider | Buys | Value |
|---|---|---|
| Opaleye Management Inc. | 6 | $2M |
| Martin A Makary | 1 | $338,400 |
| Mark L Baum | 3 | $264,025 |
Every purchase
Newest first. From SEC Form 4 filings. Insider buying across the market.
| Date | Insider | Shares | Price | Value | Filing |
|---|---|---|---|---|---|
| Apr 25, 2024 | Opaleye Management Inc. |
20,000 | $9.97 | $199,400 | Form 4 |
| Apr 23, 2024 | Opaleye Management Inc. |
11,715 | $10.29 | $120,547 | Form 4 |
| Apr 19, 2024 | Opaleye Management Inc. |
29,400 | $10.56 | $310,464 | Form 4 |
| Mar 28, 2024 | Opaleye Management Inc. |
50,000 | $12.82 | $641,000 | Form 4 |
| Mar 22, 2024 | Mark L Baum |
9,000 | $11.59 | $104,310 | Form 4 |
| Mar 20, 2024 | Opaleye Management Inc. |
50,600 | $9.65 | $488,290 | Form 4 |
| Nov 16, 2023 | Mark L Baum |
7,500 | $8.11 | $60,825 | Form 4 |
| Sep 19, 2023 | Opaleye Management Inc. |
14,017 | $14.65 | $205,349 | Form 4 |
| Aug 14, 2023 | Martin A Makary |
20,000 | $16.92 | $338,400 | Form 4 |
| Aug 14, 2023 | Mark L Baum |
5,800 | $17.05 | $98,890 | Form 4 |
Questions
Are Harrow Health insiders buying the stock?
10 open-market purchases of HROW by Harrow Health's executives and directors since August 2023, worth $3M in total, from SEC Form 4 filings. The most recent: Opaleye Management Inc. bought $199,400 on April 25, 2024.
What counts as insider buying here?
Open-market purchases (Form 4 code P) by officers and directors. Option exercises, grants and purchases by 10% owners are left out.
From Harrow Health's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.